Collins L et al
Tirzepatide, known by brand names such as Mounjaro and Zepbound , is a prescription drug used primarily for the management of chronic weight issues
[46] After completing the SURPASS-2 trial (NCT03987919), the company announced in April 2022 that tirzepatide had successfully met its clinical endpoints in obese and overweight participants without diabetes
Reduced Risk of Other Health Conditions: Alongside weight management benefits, semaglutide can potentially reduce your risk of heart attack, kidney disease, cancer, and type 2 diabetes which are often linked to weight issues
It works by activating two key hormones, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), that help regulate blood sugar, suppress appetite, and support improved metabolic function